The untapped potential of Gallium 68-PET: The next wave of 68Ga-agents

Applied Radiation and Isotopes

Volumn 76, Issue , 2013, Pages 14-23

  Smith, Daniel L ^a   Breeman, Wouter A P ^b   Sims Mourtada, Jennifer ^c  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b ERASMUS MEDICAL CENTER   (Netherlands)

^c HELEN F GRAHAM CANCER CENTER   (United States)

Author keywords

Gallium 68; PET; Preclinical studies

Indexed keywords

ISOTOPES; POLYETHYLENE TEREPHTHALATES; RADIATION;

CONVENIENT ALTERNATIVES; HALF LIVES; IMAGING APPLICATIONS; PATIENT DOSE; PET ISOTOPES; PRECLINICAL STUDIES; SUPERIOR RESOLUTION;

GALLIUM;

FLUORINE TERTRAXETAN ARGINYLGLYCYLASPARTATE F 18; FLUORODEOXYGLUCOSE F 18; GALLIUM 68; GALLIUM DOTAVAP P1 GA 68; GALLIUM EDOTREOTIDE GA 68; GALLIUM NODOGA ARGINYLGLYCYLASPARTATE GA 68; GALLIUM NODOGA LM3 GA 68; GALLIUM NOTA ARGINYLGLYCYLASPARTATE BOMBESIN GA 68; GALLIUM NOTA ARGINYLGLYCYLASPARTATE HUMAN SERUM ALBUMIN TISSUE INHIBITOR OF METALLOPROTEINASE 2 GA 68; GALLIUM RM2 GA 68; GALLIUM TERTRAXETAN ARGINYLGLYCYLASPARTATE GA 68; GALLIUM TETRAXETAN ARGINYLGLYCYLASPARTATE GA 68; GALLIUM TETRAXETAN GLYCYL 4 AMINOBENZOYL BN[7-14] GA 68; GALLIUM TETRAXETAN MINIGASTRIN GA 68; GALLIUM TETRAXETAN TYR3 OCTREOTATE GA 68; GASTRIN RELEASING PEPTIDE RECEPTOR; GLUCAGON LIKE PEPTIDE 1 RECEPTOR; INDIUM TERTRAXETAN ARGINYLGLYCYLASPARTATE IN 111; LUTETIUM TETRAXETAN GLYCYL 4 AMINOBENZOYL BN[7-14] LU 177; LYSINE(AXH TETRAXETAN GALLIUM)AMINE EXEDIN 3 GA 68; LYSINE(AXH TETRAXETAN GALLIUM)AMINE EXEDIN 4 GA 68; LYSINE(AXH TETRAXETAN INDIUM)AMINE EXEDIN 4 IN 111; NANOBODY; PROSTATE SPECIFIC ANTIGEN; RADIOPHARMACEUTICAL AGENT; SOMATOSTATIN; SOMATOSTATIN RECEPTOR 2; TETRAXETAN; UNCLASSIFIED DRUG; VASCULOTROPIN;

ARTICLE; BINDING AFFINITY; CANCER DIAGNOSIS; CHEMICAL STRUCTURE; DIAGNOSTIC IMAGING; DRUG BINDING; DRUG DISTRIBUTION; DRUG TRANSPORT; DRUG UPTAKE; HUMAN; INSULINOMA; ISOTOPE LABELING; MOLECULAR IMAGING; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROTEIN TARGETING; RECEPTOR BINDING;

EID: 84878127169     PISSN: 09698043     EISSN: 18729800     Source Type: Journal    
DOI: 10.1016/j.apradiso.2012.10.014     Document Type: Article

References (103)

1. Aalto K., Autio A., Kiss E.A., Elima K., Nymalm Y., Veres T.Z., Marttila-Ichihara F., Elovaara H., Saanijoki T., Crocker P.R., Maksimow M., Bligt E., Salminen T.A., Salmi M., Roivainen A., Jalkanen S. Siglec-9 is a novel leukocyte ligand for vascular adhesion protein-1 and can be used in PET imaging of inflammation and cancer. Blood 2011, 118(13):3725-3733.
2. Autio A., Ujula T., Luoto P., Salomã¶ki S., Jalkanen S., Roivainen A. PET imaging of inflammation and adenocarcinoma xenografts using vascular adhesion protein 1 targeting peptide 68Ga-DOTAVAP-P1: comparison with 18F-FDG. Eur. J. Nucl. Med. Mol. Imaging 2010, 37(10):1918-1925.
3. Backer M.V., Patel V., Jehning B.T., Claffey K.P., Backer J.M. Surface immobilization of active vascular endothelial growth factor via a cysteine-containing tag. Biomaterials 2006, 27(31):5452-5458.
4. Banerjee, S.R., Pullambhatla, M., Byun, Y., Nimmagadda, S., Green, G., Fox, J.J., Horti, A., Mease, R.C., M.G., Pomper. 68Ga-labeled inhibitors of prostate-specific membrane antigen (PSMA) for imaging prostate cancer. J. Med. Chem. 53(14): 5333-5341.
5. Banerjee S.R., Foss C.A., Castanares M., Mease R.C., Byun Y., Fox J.J., Hilton J., Lupold S.E., Kozikowski A.P., Pomper M.G. Synthesis and evaluation of technetium-99m and rhenium-labeled inhibitors of the prostate-specific membrane antigen (PSMA). J. Med. Chem. 2008, 51(15):4504-4517.
6. Blom E., Velikyan I., Monazzam A., Razifar P., Nair M., Razifar P., Vanderheyden J.L., Krivoshein A.V., Backer M., Backer J., LÃyngström B. Synthesis and characterization of scVEGF-PEG-[68Ga]NOTA and scVEGF-PEG-[68Ga]DOTA PET tracers. J. Labelled Compd. Radiopharm. 2011, 54(11):685-692.
7. Bodei L., Ferrari M., Nunn A.D., et al. Bombesin analog in hormone refractory prostate cancer patients: a phase 1 escalation study with single-cycle administrations. Eur. J. Nucl. Med. Mol. Imaging 2007, 34:S221.
8. Boerman O.C., van Schaijk F.G., Oyen W.J., Corstens F.H. Pretargeted radioimmunotherapy of cancer: progress step by step. J. Nucl. Med. 2003, 44(3):400-411.
9. Breeman W.A., Kwekkeboom D.J., Kooij P.P., Bakker W.H., Hofland L.J., Visser T.J., Ensing G.J., Lamberts S.W., Krenning E.P. Effect of dose and specific activity on tissue distribution of indium-111-pentetreotide in rats. J. Nucl. Med. 1995, 36(4):623-627.
10. Breeman W.A., VanHagen M.P., Visser-Wisselaar H.A., van der Pluijm M.E., Koper J.W., Setyono-Han B., Bakker W.H., Kwekkeboom D.J., Hazenberg M.P., Lamberts S.W., Visser T.J., Krenning E.P. In vitro and in vivo studies of substance P receptor expression in rats with the new analog [indium-111-DTPA-Arg1]substance P. J. Nucl. Med. 1996, 37(1):108-117.
11. Breeman W.A., De Jong M., Bernard B.F., Kwekkeboom D.J., Srinivasan A., van der Pluijm M.E., Hofland L.J., Visser T.J., Krenning E.P. Pre-clinical evaluation of [(111)In-DTPA-Pro(1), Tyr(4)]bombesin, a new radioligand for bombesin-receptor scintigraphy. Int. J. Cancer 1999, 83(5):657-663.
12. Breeman W.A., de Jong M., Kwekkeboom D.J., Valkema R., Bakker W.H., Kooij P.P., Visser T.J., Krenning E.P. Somatostatin receptor-mediated imaging and therapy: basic science, current knowledge, limitations and future perspectives. Eur. J. Nucl. Med. 2001, 28(9):1421-1429.
13. Breeman W.A.P., de Blois E., Chan H.S., Krenning E.P. Maintaining radiochemical purity of peptides for receptor-targeting. J. Labelled Compd. Radiopharm. 2009, 52(1):S270.
14. Brom, M., Joosten L., Laverman, P., Oyen, W.J., Behe, M., Gotthardt M., Boerman O.C., 2010. Preclinical evaluation of 68Ga-DOTA-minigastrin for the detection of cholecystokinin-2/gastrin receptor-positive tumors. Mol. Imaging 10(2): 144-152.
15. Brom, M., Oyen, W.J., Joosten, L., Gotthardt, M., Boerman O.C., 2011. 68Ga-labelled exendin-3, a new agent for the detection of insulinomas with PET. Eur. J. Nucl. Med. Mol Imaging 37(7): 1345-1355.
16. Brooks P.C., Clark R.A.F., Cheresh D.A. Requirement of vascular integrin α(v)α3 for angiogenesis. Science 1994, 264(5158):569-571.
17. Cagnolini, A., Chen, J., Ramos, K., Skedzielewski, T.M., Lantry, L.E., Nunn, A.D., Swenson, R.E., Linder, K.E. Automated synthesis, characterization and biological evaluation of [(68)Ga]Ga-AMBA, and the synthesis and characterization of (nat)Ga-AMBA and [(67)Ga]Ga-AMBA. Appl. Radiat. Isot. 68(12): 2285-2292.
18. Cai W., Olafsen T., Zhang X., Cao Q., Gambhir S.S., Williams L.E., Wu A.M., Chen X. PET imaging of colorectal cancer in xenograft-bearing mice by use of an 18F-labeled T84.66 anti-carcinoembryonic antigen diabody. J. Nucl. Med. 2007, 48(2):304-310.
19. Capala, J., Bouchelouche K., 2010. Molecular imaging of HER2-positive breast cancer: a step toward an individualized 'image and treat' strategy. Curr. Opin. Oncol. 22(6): 559-566.
20. Chaux, A., Eifler, J., Karram, S., Al-Hussain, T., Faraj, S., Pomper, M., Focal positive prostate-specific membrane antigen (PSMA) expression in ganglionic tissues associated with prostate neurovascular bundle: implications for novel intraoperative PSMA-based fluorescent imaging techniques. Urol. Oncol. in press, Epub ahead of print, Jun 1 2011.
21. Chen Y., Foss C.A., Byun Y., Nimmagadda S., Pullambhatla M., Fox J.J., Castanares M., Lupold S.E., Babich J.W., Mease R.C., Pomper M.G. Radiohalogenated prostate-specific membrane antigen (PSMA)-based ureas as imaging agents for prostate cancer. J. Med. Chem. 2008, 51(24):7933-7943.
22. Chen Y., Dhara S., Banerjee S.R., Byun Y., Pullambhatla M., Mease R.C., Pomper M.G. A low molecular weight PSMA-based fluorescent imaging agent for cancer. Biochem. Biophys. Res. Commun. 2009, 390(3):624-629.
23. Cheng Z., De Jesus O.P., Namavari M., De A., Levi J., Webster J.M., Zhang R., Lee B., Syud F.A., Gambhir S.S. Small-animal PET imaging of human epidermal growth factor receptor type 2 expression with site-specific 18F-labeled protein scaffold molecules. J. Nucl. Med. 2008, 49(5):804-813.
24. Choi N., Kim S.M., Hong K.S., Cho G., Cho J.H., Lee C., Ryu E.K. The use of the fusion protein RGD-HSA-TIMP2 as a tumor targeting imaging probe for SPECT and PET. Biomaterials 2011, 32(29):7151-7158.
25. Christ E., Wild D., Forrer F., Brandle M., Sahli R., Clerici T., Gloor B., Martius F., Maecke H., Reubi J.C. Glucagon-like peptide-1 receptor imaging for localization of insulinomas. J. Clin. Endocrinol. Metab. 2009, 94(11):4398-4405.
26. Dadparvar S., Krishna L., Miyamoto C., Brady L.W., Brown S.J., Bender H., Slizofski W.J., Eshleman J., Chevres A., Woo D.V. Indium-111-labeled anti-EGFr-425 scintigraphy in the detection of malignant gliomas. Cancer 1994, 73(3):884-889.
27. De Vita, V.J.H.S.R.S., Ed., 1995. Principles and Practices of Oncology. The role of radiolabeld somatostatin analotues in the management of cancer patients. Philadelphia, Lippencott-Raven.
28. 111In-labelled DOTA-RGD peptides for imaging of αvα3 integrin expression. Eur. J. Nucl. Med. Mol. Imaging 2008, 35(8):1507-1515.
29. Dharmsathaphorn K., Sherwin R.S., Cataland S., Jaffe B., Dobbins J. Somatostatin inhibits diarrhea in the carcinoid syndrome. Ann. Intern. Med. 1980, 92(1):68-69.
30. Dijkgraaf I., Kruijtzer J.A.W., Liu S., Soede A.C., Oyen W.J.G., Corstens F.H.M., Liskamp R.M.J., Boerman O.C. Improved targeting of the αvα3 integrin by multimerisation of RGD peptides. Eur. J. Nucl. Med. Mol. Imaging 2007, 34(2):267-273.
31. 68Ga-labelled mono-, di- and tetrameric RGD peptides. Eur. J. Nucl. Med. Mol. Imaging 2011, 38(1):128-137.
32. 68Ga-labeled RGD conjugates show improved PET imaging of αÎ1/2α3 integrin expression and facile radiosynthesis. J. Nucl. Med. 2011, 52(8):1276-1284.
33. Eder, M., Knackmuss, S., Le Gall, F., Reusch, U., Rybin, V., Little, M., Haberkorn, U., Mier, W., Eisenhut M., 2010a. 68Ga-labelled recombinant antibody variants for immuno-PET imaging of solid tumours. Eur. J. Nucl. Med. Mol. Imaging 37(7): 1397-1407.
34. Eder M., Krivoshein A.V., Backer M., Backer J.M., Haberkorn U., Eisenhut M. ScVEGF-PEG-HBED-CC and scVEGF-PEG-NOTA conjugates: comparison of easy-to-label recombinant proteins for [68Ga]PET imaging of VEGF receptors in angiogenic vasculature. Nucl. Med. Biol. 2010, 37(4):405-412.
35. Eliceiri B.P., Cheresh D.A. The role of αv integrins during angiogenesis: Insights into potential mechanisms of action and clinical development. J. Clin. Invest. 1999, 103(9):1227-1230.
36. Fani, M., Del Pozzo, L., Abiraj, K., Mansi, R., Tamma, M.L., Cescato, R., Waser, B., Weber, W.A., Reubi, J.C., Maecke, H.R., 2011. PET of somatostatin receptor-positive tumors using 64Cu- and 68Ga-somatostatin antagonists: the chelate makes the difference. J. Nucl. Med. 52(7): 1110-1118.
37. Fani, M., Mueller A., Tamma M.L., Nicolas G., Rink H.R., Cescato R., Reubi J.C., Maecke H.R., 2010. Radiolabeled bicyclic somatostatin-based analogs: a novel class of potential radiotracers for SPECT/PET of neuroendocrine tumors. J. Nucl. Med 51(11): 1771-17719.
38. Feldwisch, J., Tolmachev, V., Carlsson, J., Stahl, S., Frejd, F.Y., 2010. Affibody molecules: engineered proteins for therapeutic, diagnostic and biotechnological applications. FEBS Lett. 584(12): 2670-2680.
39. Ferrara N. Vascular endothelial growth factor: basic science and clinical progress. Endocr. Rev. 2004, 25(4):581-611.
40. Ferrara N., Gerber H.P., LeCouter J. The biology of VEGF and its receptors. Nat. Med. 2003, 9(6):669-676.
41. Frolich J.C., Bloomgarden Z.T., Oates J.A., McGuigan J.E., Rabinowitz D. The carcinoid flush. Provocation by pentagastrin and inhibition by somatostatin. N. Engl. J. Med. 1978, 299(19):1055-1057.
42. Furukawa T., Fujibayashi Y., Fukunaga M., Saga T., Endo K., Yokoyama A. An approach for immunoradiometric assay with metallic radionuclides: gallium-67-deferoxamine-dialdehyde starch-IgG. J. Nucl. Med. 1991, 32(5):825-829.
43. Ginj M., Zhang H., Waser B., Cescato R., Wild D., Wang X., Erchegyi J., Rivier J., Macke H.R., Reubi J.C. Radiolabeled somatostatin receptor antagonists are preferable to agonists for in vivo peptide receptor targeting of tumors. Proc. Natl. Acad. Sci. USA 2006, 103(44):16436-16441.
44. Gotthardt M., Behe M.P., Beuter D., Battmann A., Bauhofer A., Schurrat T., Schipper M., Pollum H., Oyen W.J., Behr T.M. Improved tumour detection by gastrin receptor scintigraphy in patients with metastasised medullary thyroid carcinoma. Eur. J. Nucl. Med. Mol. Imaging 2006, 33(11):1273-1279.
45. Gotthardt M., Behe M.P., Grass J., Bauhofer A., Rinke A., Schipper M.L., Kalinowski M., Arnold R., Oyen W.J., Behr T.M. Added value of gastrin receptor scintigraphy in comparison to somatostatin receptor scintigraphy in patients with carcinoids and other neuroendocrine tumours. Endocr. Relat. Cancer 2006, 13(4):1203-1211.
46. Haubner R., Wester H.J., Reuning U., Senekowitsch-Schmidtke R., Diefenbach B., Kessler H., Stöcklin G., Schwaiger M. Radiolabeled α(Î1/2)α3 integrin antagonists: A new class of tracers for tumor targeting. J. Nucl. Med. 1999, 40(6):1061-1071.
47. 68Ga-DOTA-RGD peptide: Biodistribution and binding into atherosclerotic plaques in mice. Eur. J. Nucl. Med. Mol. Imaging 2009, 36(12):2058-2067.
48. 68GA]DOTA-D-Phe1-Tyr3-octreotide: first results in patients with meningiomas. J. Nucl. Med. 2001, 42(7):1053-1056.
49. Hofmann M., Maecke H., Borner R., Weckesser E., Schoffski P., Oei L., Schumacher J., Henze M., Heppeler A., Meyer J., Knapp H. Biokinetics and imaging with the somatostatin receptor PET radioligand (68)Ga-DOTATOC: preliminary data. Eur J. Nucl. Med. 2001, 28(12):1751-1757.
50. Hood J.D., Cheresh D.A. Role of integrins in cell invasion and migration. Nat. Rev. Cancer 2002, 2(2):91-100.
51. Hudson P.J., Kortt A.A. High avidity scFv multimers; diabodies and triabodies. J. Immunol. Methods 1999, 231(1-2):177-189.
52. Irjala H., Salmi M., Alanen K., Grénman R., Jalkanen S. Vascular adhesion protein 1 mediates binding of immunotherapeutic effector cells to tumor endothelium. J. Immunol. 2001, 166(11):6937-6943.
53. Jalkanen S., Karikoski M., Mercier N., Koskinen K., Henttinen T., Elima K., Salmivirta K., Salmi M. The oxidase activity of vascular adhesion protein-1 (VAP-1) induces endothelial E- and P-selectins and leukocyte binding. Blood 2007, 110(6):1864-1870.
54. Janssen M., Oyen W.J.G., Massuger L.F.A.G., Frielink C., Dijkgraaf I., Edwards D.S., Radjopadhye M., Corstens F.H.M., Boerman O.C. Comparison of a monomeric and dimeric radiolabeled RGD-peptide for tumor targeting. Cancer Biother. Radiopharm. 2002, 17(6):641-646.
55. 68Ga-labeled c(RGDyK)-isothiocyanatobenzyl-1,4,7-triazacyclononane-1, 4,7-triacetic acid and feasibility studies in mice. J. Nucl. Med. 2008, 49(5):830-836.
56. Kaemmerer, D., Khatib-Chahidi, K., Paul Baum, R., Horsch, D., Presselt, N., Sanger, J., Kunze, A., Hommann, M., 2011. Concomitant lung and gastroenteropancreatic neuroendocrine tumors and the value of gallium-68 PET/CT. Cancer Imaging 11: 179-183.
57. Knetsch P.A., Petrik M., Griessinger C.M., Rangger C., Fani M., Kesenheimer C., Von Guggenberg E., Pichler B.J., Virgolini I., Decristoforo C., Haubner R. NODAGA-RGD for imaging αvα3 integrin expression. Eur. J. Nucl. Med. Mol. Imaging 2011, 38(7):1303-1312.
58. Korner M., Stockli M., Waser B., Reubi J.C. GLP-1 receptor expression in human tumors and human normal tissues: potential for in vivo targeting. J. Nucl. Med. 2007, 48(5):736-743.
59. Koskinen K., Vainio P.J., Smith D.J., Pihlavisto M., YlÃ-Herttuala S., Jalkanen S., Salmi M. Granulocyte transmigration through the endothelium is regulated by the oxidase activity of vascular adhesion protein-1 (VAP-1). Blood 2004, 103(9):3388-3395.
60. 111In]-DTPAOC SPECT. First results in patients with neuroendocrine tumors. Mol. Imaging Biol. 2003, 5(1):42-48.
61. Kramer-Marek, G., Shenoy, N., Seidel, J., Griffiths, G.L., Choyke, P., Capala, J. 68Ga-DOTA-affibody molecule for in vivo assessment of HER2/neu expression with PET. Eur. J. Nucl. Med. Mol. Imaging 38(11): 1967-1976.
62. 18F]FBEM-Z(HER2:342)-Affibody molecule-a new molecular tracer for in vivo monitoring of HER2 expression by positron emission tomography. Eur. J. Nucl. Med. Mol. Imaging 2008, 35(5):1008-1018.
63. Lalor P.F., Sun P.J., Weston C.J., Martin-Santos A., Wakelam M.J.O., Adams D.H. Activation of vascular adhesion protein-1 on liver endothelium results in an NF-ΰB-dependent increase in lymphocyte adhesion. Hepatology 2007, 45(2):465-474.
64. Lamberts S.W., Uitterlinden P., Verschoor L., van Dongen K.J., del Pozo E. Long-term treatment of acromegaly with the somatostatin analog SMS 201-995. N. Engl. J. Med. 1985, 313(25):1576-1580.
65. Lang L., Li W., Guo N., Ma Y., Zhu L., Kiesewetter D.O., Shen B., Niu G., Chen X. Comparison study of [18F]FAl-NOTA-PRGD2, [18F] FPPRGD2, and [68Ga]Ga-NOTA-PRGD2 for PET imaging of u87mg tumors in mice. Bioconjugate Chem. 2011, 22(12):2415-2422.
66. 68Ga-DOTAVAP-P1 PET imaging capable of demonstrating the phase of inflammation in healing bones and the progress of infection in osteomyelitic bones. Eur. J. Nucl. Med. Mol. Imaging 2008, 35(2):352-364.
67. 68Ga-labeled multimeric RGD peptides for microPET imaging of integrin αvα3 expression. Eur. J. Nucl. Med. Mol. Imaging 2008, 35(6):1100-1108.
68. 68Ga-labeled cyclic RGD dimers with Gly3 and PEG 4 linkers: promising agents for tumor integrin α vα3 PET imaging. Eur. J. Nucl. Med. Mol. Imaging 2009, 36(6):947-957.
69. 68Ga-labeled NOTA-RGD-BBN peptide for dual integrin and GRPR-targeted tumor imaging. Eur. J. Nucl. Med. Mol. Imaging 2009, 36(9):1483-1494.
70. 68Ga labeled RGD-bombesin heterodimeric peptides for PET imaging of breast cancer. Bioconjugate Chem. 2009, 20(5):1016-1025.
71. Mansi, R., Wang X., Forrer F., Waser B., Cescato, R., Graham, K., Borkowski, S., Reubi, J.C., Maecket, H.R., 2011. Development of a potent DOTA-conjugated bombesin antagonist for targeting GRPr-positive tumours. Eur. J. Nucl. Med. Mol. Imaging 38(1): 97-107.
72. Naswa, N., Sharma, P., Kumar, A., Nazar, A.H., Kumar, R., Chumber S., Bal C. 68Gallium-DOTA-NOC PET/CT of patients with gastroenteropancreatic neuroendocrine tumors: a prospective single-center study. AJR Am. J. Roentgenol. 197(5): 1221-1228.
73. Noël A., Hajitou A., L'Hoir C., Maquoi E., Baramova E., Lewalle J.M., Remacle A., Kebers F., Brown P., Calberg-Bacq C.M., Foidart J.M. Inhibition of stromal matrix metalloproteases: Effects on breast-tumor promotion by fibroblasts. Int. J. Cancer 1998, 76(2):267-273.
74. Olafsen T., Kenanova V.E., Sundaresan G., Anderson A.L., Crow D., Yazaki P.J., Li L., Press M.F., Gambhir S.S., Williams L.E., Wong J.Y., Raubitschek A.A., Shively J.E., Wu A.M. Optimizing radiolabeled engineered anti-p185HER2 antibody fragments for in vivo imaging. Cancer Res. 2005, 65(13):5907-5916.
75. Orlova A., Wallberg H., Stone-Elander S., Tolmachev V. On the selection of a tracer for PET imaging of HER2-expressing tumors: direct comparison of a 124I-labeled affibody molecule and trastuzumab in a murine xenograft model. J. Nucl. Med. 2009, 50(3):417-425.
76. Palyga, I., Kowalska, A., Gasior-Perczak, D., Tarnawska-Pierscinska, M., Sluszniak, J., Sygut, J., Gozdz S., 2010. The role of PET-CT scan with somatostatin analog labelled with gallium-68 (Ga-DOTA-TATE PET-CT) in diagnosing patients with disseminated medullary thyroid carcinoma (MTC). Endocrinol. Pol. 61(5): 507-511.
77. Plow E.F., Haas T.A., Zhang L., Loftus J., Smith J.W. Ligand binding to integrins. J. Biol. Chem. 2000, 275(29):21785-21788.
78. Reubi J.C., Kvols L. Somatostatin receptors in human renal cell carcinomas. Cancer Res. 1992, 52(21):6074-6078.
79. Reubi J.C., Waser B. Concomitant expression of several peptide receptors in neuroendocrine tumours: molecular basis for in vivo multireceptor tumour targeting. Eur. J. Nucl. Med. Mol. Imaging 2003, 30(5):781-793.
80. Reubi J.C., Waser B., Schaer J.C., Laissue J.A. Somatostatin receptor sst1-sst5 expression in normal and neoplastic human tissues using receptor autoradiography with subtype-selective ligands. Eur. J. Nucl. Med. 2001, 28(7):836-846.
81. Roovers R.C., Laeremans T., Huang L., De Taeye S., Verkleij A.J., Revets H., de Haard H.J., Henegouwen P.M.van Bergen en Efficient inhibition of EGFR signaling and of tumour growth by antagonistic anti-EFGR nanobodies. Cancer Immunol. Immunother. 2007, 56(3):303-317.
82. Roovers R.C., van Dongen G.A., Henegouwen P.M.van Bergen en Nanobodies in therapeutic applications. Curr. Opin. Mol. Ther. 2007, 9(4):327-335.
83. 99mTc-labeled C225 in patients with squamous cell carcinoma of the head and neck. J. Nucl. Med. 2004, 45(10):1683-1687.
84. Schoffelen, R., van der Graaf, W.T., Sharkey, R.M., Franssen, G.M., McBride, W.J., Chang, C.H., Laverman, P., Goldenberg, D.M., Oyen, W.J., Boerman, O.C., 2012. Pretargeted immuno-PET of CEA-expressing intraperitoneal human colonic tumor xenografts: a new sensitive detection method. EJNMMI Res. 2:5.
85. Shroeder, R.P., van Weerden, W.M., Krenning, E.P., Bangma, C.H., Berndsen, S., Grievink-de Ligt, C.H., Groen, H.C., Reneman, S., de Blois, E., Breeman, W.A., Jong M. de 2012. Gastrin-releasing peptide receptor-based targeting using bombesin analogs is superior to metabolism-based targeting using choline for in vivo imaging of human prostate cancer xenografts. Eur. J. Nucl. Med. Mol. Imaging 38(7): 1257-1266.
86. 68Ga-DOTAVAP-PEG-P2 peptide targeting vascular adhesion protein-1. Clin. Physiol. Funct. Imaging 2010, 30(1):75-78.
87. Smith-Jones P.M., Stolz B., Bruns C., Albert R., Reist H.W., Fridrich R., Macke H.R. Gallium-67/gallium-68-[DFO]-octreotide--a potential radiopharmaceutical for PET imaging of somatostatin receptor-positive tumors: synthesis and radiolabeling in vitro and preliminary in vivo studies. J. Nucl. Med. 1994, 35(2):317-325.
88. Sundaresan G., Yazaki P.J., Shively J.E., Finn R.D., Larson S.M., Raubitschek A.A., Williams L.E., Chatziioannou A.F., Gambhir S.S., Wu A.M. 124I-labeled engineered anti-CEA minibodies and diabodies allow high-contrast, antigen-specific small-animal PET imaging of xenografts in athymic mice. J. Nucl. Med. 2003, 44(12):1962-1969.
89. Tijink B.M., Laeremans T., Budde M., Stigter-van Walsum M., Dreier T., de Haard H.J., Leemans C.R., Dongen G.A.van Improved tumor targeting of anti-epidermal growth factor receptor Nanobodies through albumin binding: taking advantage of modular Nanobody technology. Mol. Cancer Ther. 2008, 7(8):2288-2297.
90. Todorovska A., Roovers R.C., Dolezal O., Kortt A.A., Hoogenboom H.R., Hudson P.J. Design and application of diabodies, triabodies and tetrabodies for cancer targeting. J. Immunol. Methods 2001, 248(1-2):47-66.
91. Tolmachev, V., Velikyan, I., Sandstrom, M., Orlova, A. A HER2-binding Affibody molecule labelled with 68Ga for PET imaging: direct in vivo comparison with the 111In-labelled analog. Eur. J. Nucl. Med. Mol. Imaging 37(7): 1356-1367.
92. Treglia, G., Castaldi P., Rindi G., Giordano A. and Rufini V. Diagnostic performance of Gallium-68 somatostatin receptor PET and PET/CT in patients with thoracic and gastroenteropancreatic neuroendocrine tumours: a meta-analysis. Endocrine.
93. Ujula T., Salomöki S., Virsu P., Lankinen P., Mökinen T.J., Autio A., Yegutkin G.G., Knuuti J., Jalkanen S., Roivainen A. Synthesis, 68Ga labeling and preliminary evaluation of DOTA peptide binding vascular adhesion protein-1: a potential PET imaging agent for diagnosing osteomyelitis. Nuclear Medicine and Biology 2009, 36(6):631-641.
94. Van C.de Wiele, Phonteyne P., Pauwels P., Goethals I., Van den Broecke R., Cocquyt V., Dierckx R.A. Gastrin-releasing peptide receptor imaging in human breast carcinoma versus immunohistochemistry. J. Nucl. Med. 2008, 49(2):260-264.
95. Van de Wiele C., Dumont F., Vanden Broecke R., Oosterlinck W., Cocquyt V., Serreyn R., Peers S., Thornback J., Slegers G., Dierckx R.A. Technetium-99m RP527, a GRP analog for visualisation of GRP receptor-expressing malignancies: a feasibility study. Eur. J. Nucl. Med. 2000, 27(11):1694-1699.
96. Veber D.F., Holly F.W., Paleveda W.J., Nutt R.F., Bergstrand S.J., Torchiana M., Glitzer M.S., Saperstein R., Hirschmann R. Conformationally restricted bicyclic analogs of somatostatin. Proc. Natl. Acad. Sci. USA 1978, 75(6):2636-2640.
97. Veber D.F., Holly F.W., Nutt R.F., Bergstrand S.J., Brady S.F., Hirschmann R., Glitzer M.S., Saperstein R. Highly active cyclic and bicyclic somatostatin analogs of reduced ring size. Nature 1979, 280(5722):512-514.
98. Velikyan, I., Sundin, A., Eriksson, B., Lundqvist, H., Sorensen, J., Bergstrom, M., Langstrom B., 2010. In vivo binding of [68Ga]-DOTATOC to somatostatin receptors in neuroendocrine tumours-impact of peptide mass. Nucl. Med. Biol. 37(3): 265-275.
99. Velikyan I., Sundberg A.L., Lindhe O., Hoglund A.U., Eriksson O., Werner E., Carlsson J., Bergstrom M., Langstrom B., Tolmachev V. Preparation and evaluation of (68)Ga-DOTA-hEGF for visualization of EGFR expression in malignant tumors. J. Nucl. Med. 2005, 46(11):1881-1888.
100. Vosjan, M.J., Perk, L.R., Roovers, R.C., Visser, G.W., Stigter-van Walsum, M., HenegouwenP.M. van Bergen En, Dongen, G.A. van, 2008. Facile labelling of an anti-epidermal growth factor receptor Nanobody with 68Ga via a novel bifunctional desferal chelate for immuno-PET. Eur. J. Nucl. Med. Mol. Imaging 38(4): 753-763.
101. Wild, D., Wicki, A., Mansi, R., Behe M., Keil, B., Bernhardt, P., Christofori, G., Ell, P.J., Macke, H.R., 2010. Exendin-4-based radiopharmaceuticals for glucagonlike peptide-1 receptor PET/CT and SPECT/CT. J. Nucl. Med. 51(7): 1059-1067.
102. Yoong K.F., McNab G., HÃ1/4bscher S.G., Adams D.H. Vascular adhesion protein-1 and ICAM-1 support the adhesion of tumor infiltrating lymphocytes to tumor endothelium in human hepatocellular carcinoma. J. Immunol. 1998, 160(8):3978-3988.
103. Zhang H., Chen J., Waldherr C., Hinni K., Waser B., Reubi J.C., Maecke H.R. Synthesis and evaluation of bombesin derivatives on the basis of pan-bombesin peptides labeled with indium-111, lutetium-177, and yttrium-90 for targeting bombesin receptor-expressing tumors. Cancer Res. 2004, 64(18):6707-6715.